Editorial

From the desk of the editor

Welcome to the May 2013 edition of i2P - Information to pharmacists.
Economic turbulence seems to now be arriving in Australia with forecasts of high inflation rates, which also means high interest rates following on.
This type of economic forecast also means that banks will be more fractious with their borrowers. They are already offside with pharmacy due to the high level of bankruptcies over the past two years.
There is a pent up demand for a general wage increase for pharmacists impacting at a point in this month where pharmacy gross profit generally, is in decline.

read more
open full screen

Columns

Recent Comments

Click here to read...

Past Editions

Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 4 Number 1
Volume 4 Number 2
Volume 4 Number 3
Volume 4 Number 4
Volume 4 Number 5
Volume 4 Number 6
Volume 4 Number 7
Volume 4 Number 8
Volume 4 Number 9
Volume 4 Number 10
Volume 4 Number 11
Volume 5 Number 1
Volume 5 Number 2
Volume 5 Number 3
Volume 5 Number 4

i2P Archives

Health Politics

EPublications

Click here for a list of epublications

Tea tree oil offers hope to skin cancer patients

• Printer-friendly version
• Send to friend
• PDF version
• Share

	Staff Writer articles by this author...
Editing and Researching news and stories about global and local Pharmacy Issues

Tea tree oil may be used in future as a fast, cheap, safe and effective treatment for non-melanoma skin cancers and precancerous lesions, according to researchers at The University of Western Australia.
A three-year study by the University of Western Australia Tea Tree Oil Research Group has found solid tumours grown under the skin in mice and treated with a tea tree oil formulation causes inhibition of tumour growth and tumour regression within a day of treatment. Within three days, the tumours cannot be detected.

open this article full screen

The study by research associates Dr Sara Greay and Dr Demelza Ireland of UWA's School of Biomedical, Biomolecular and Chemical Sciences and colleagues was published online in the journal Cancer Chemotherapy Pharmacology.
It was carried out in collaboration with Rural Industries Research and Development Corporation (RIRDC) and Novasel Pty. Ltd. Dr Greay said further experiments indicated the anti-cancer effect of the tea tree oil formulation appeared to involve activation of the immune system.
"We are very excited about these results and are hoping to find funding for a small clinical trial of about 50 people with pre-cancerous lesions, with the aim of preventing the development of skin cancers," Dr Greay said.
Unlike other clinically approved skin cancer chemotherapies, which have long treatment times of three to 16 weeks and can cause nausea and flu-like symptoms, the tea tree oil formulation only produces mild skin irritation which disappears within days of treatment finishing.
"We believe the formulation is crucial to prevent the evaporation and increase the penetration of tea tree oil through the skin," Dr Greay said.
Australia has the highest incidence of skin cancer worldwide with around 434,000 Australians treated for one or more non-melanoma skin cancers every year. In addition, in 2001, Cancer Council Australia estimated the treatment of non-melanoma skin cancer cost $264 million.
Tea tree oil is a natural, renewable resource from Melaleuca alternifolia, a tree native to New South Wales. Increased demand for the oil would strengthen the industry and, besides the medical benefits, would also benefit the rural communities based on the production of the oil.
Dr Greay, Dr Ireland and their colleagues Haydn Kissick, Dr Christine Carson, Winthrop Professor Tom Riley and Associate Professor Manfred Beilharz were funded by the RIRDC and Novasel Pty Ltd.

Clinical Newsfeed

Click here to read more...

Research Reports

Practice Development

Preventive Medicine

i2P Alliance Partners